^
Association details:
| Biomarker: | FOXA mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) + ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).
Published date:
05/13/2020
Excerpt:
We evaluated ctDNA in serial plasma samples from patients enrolled in A.MARTIN (NCT01485861), a randomized phase II study of abiraterone with or without ipatasertib in patients with mCRPC...Lastly, we explored CNVs and observed emerging resistance mutations in progression samples, including alterations in TP53, AR, FOXA, PTEN, and PI3K/AKT pathway genes.
DOI:
10.1200/JCO.2020.38.15_suppl.5508
Trial ID:
